# The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib

> **NCT04179890** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 462 (actual)

## Conditions studied

- Non-squamous, Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Afatinib (Gi(l)otrif®)
- **DRUG:** Erlotinib (Tarceva®)
- **DRUG:** Gefitinib (IRESSA®)
- **DRUG:** Osimertinib (Tagrisso®)
- **DRUG:** Afatinib (Gi(l)otrif®)
- **DRUG:** Osimertinib (Tagrisso®)

## Key facts

- **NCT ID:** NCT04179890
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-17
- **Primary completion:** 2021-07-22
- **Final completion:** 2021-07-22
- **Target enrollment:** 462 (ACTUAL)
- **Last updated:** 2023-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04179890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04179890, "The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04179890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*